September 15-17, 2014
Sheraton Seattle Hotel, Seattle, WA
Tumor collections provide insight into the great variability of cancer, its progression and its response to treatment. Patient xenografts and cell models (PDX) allow researchers to link and integrate information and determine personal variations in cancer molecular profiles. The recent advancements in high-throughput genomics, proteomics and other -omics platforms allow profiling of large numbers of cancer analytes in a single assay. Thus, knowledge of these altered molecular landscapes offers great promise for developing molecular tests to improve cancer diagnosis and optimize treatment. Cambridge Healthtech Institute's Inaugural Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change convenes international oncology experts in the fields of tumor biospecimen research, PDX models, molecular diagnostics/prognostics and pharmacogenomics.